Aushon BioSystems launched this week new human multiplex biomarker panels for the quantification of eight protein biomarkers related to drug-induced kidney damage.
The panels are validated for analysis of the following biomarkers in urine samples: KIM-1, clusterin, TIMP-1, VEGF, trefoil factor-3, osteopontin, EGF, and NGAL. The panels were developed with the Aushon SearchLight protein array technology and feature a 3.5 hour protocol similar to standard plate-based ELISAs, the company said.